Radioantibody startup led by prostate cancer experts raises $90M
Neil Bander’s lab developed the first antibodies that target PSMA — a marker on prostate cancer cells that would much later become the target for Novartis’ blockbuster-hopeful radioligand therapy Pluvicto. Now, as the targeted radiotherapy field takes flight, Bander’s own biotech company hopes to develop a new treatment for prostate cancer.
Convergent Therapeutics, which was founded in late 2020 by Bander and CEO Philip Kantoff, who was previously chair of Memorial Sloan Kettering’s Department of Medicine, said Wednesday that it raised a $90 million Series A from OrbiMed, RA Capital and Invus. The biotech is developing a radioantibody dubbed CONV01-α that uses a rare isotope known as actinium and targets PSMA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.